Puma Biotechnology has completed patient enrolment in the Phase III NALA trial of its lead drug candidate PB272 (neratinib) for the treatment of HER2-positive metastatic breast cancer.

The trial of PB272 plus Xeloda versus Tykerb plus Xeloda is designed for patients who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease, and has now been completed.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Around 600 patients who are randomised (1:1) to receive either PB272 plus Xeloda or Tykerb plus Xeloda have been enrolled in the trial, which is being conducted at sites in North America, Europe and Asia-Pacific.

The trial's co-primary endpoints are progression-free survival (PFS) and overall survival (OS).

Puma Biotechnology president and chief executive officer Alan Auerbach said: "We are very pleased to achieve this important milestone for the Phase III NALA trial of neratinib in HER2-positive metastatic breast cancer.

"We are very pleased to achieve this important milestone for the Phase III NALA trial of neratinib in HER2-positive metastatic breast cancer."

"We look forward to reporting initial data from the study, which we anticipate will occur during the first half of 2018.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We also look forward to the continued development of neratinib in combination with Kadcyla in HER2-positive metastatic breast cancer (FB-10 trial), in patients with HER2-positive breast cancer that has metastasised to the brain (TBCRC-022 trial), and in patients with HER2 non-amplified tumours that have a HER2 mutation (SUMMIT)."

Puma reached an agreement with the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design of the Phase III trial.

The European Medicines Agency (EMA) has also provided follow-on scientific advice (SA) consistent with that of the FDA regarding the company's Phase III trial design and endpoints used in the trial.

The company intends to report a primary analysis of PFS during the first half of next year.